Background: We conducted a phase I-II trial to assess the activity of standard-dose (SDC) and high-dose chemotherapy (HDC) with etoposide, ifosfamide, cis/carboplatin, and epirubicin (VIP-E, VIC-E) in 107 patients with limited-stage (LS, stage I-IIIB) and extensive stage (ES, stage IV) non-small-cell lung cancer (NSCLC).
Introduction
In a phase I-II trial, the initial results of which were published in 1997 [1], we assessed the feasibility and activity of etoposide, ifosfamide, cisplatin/carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer. We present here the updated results of the trial at a median follow-up of five years.
Follow-up
Patients were enrolled between 1989 and 1995. Recruitment was stopped in December 1995, and follow-up was censored as of 1 December 1998. None of the patients were lost to follow-up. The median follow-up of all patients from time of therapy was 62 months (range 38-94 months), and that of the remaining five living patients is 52 months (range 35-76). Median duration of response and survival were assessed by the methods described by Kaplan-Meier [2] .
Patients and methods

Patient characteristics, treatment plan
Briefly, standard-dose chemotherapy (SDC) consisted of etoposide 500 mg/m 2 , ifosfamide 4000 mg/m 2 , cis-platin 50 mg/m 2 , and epirubicin 50 mg/m 2 (VIP-E) for at least two cycles. Patients with complete (CR) or partial remission (PR), and no impaired organ function after VIP-E proceeded to high-dose chemotherapy (HDC). HDC consisted of etoposide 1500 mg/m 2 , ifosfamide 12,000 mg/m 2 , carboplatin 750 mg/m 2 , and epirubicin 150 mg/m 2 (VIC-E) followed by autologous peripheral blood stem-cell transplantation (PBSCT). Surgical resection was performed if feasible. Thoracic radiation therapy (TRT) was given after HDC and in patients with PR/CR after SDC. For further details we refer to the original publication [1].
Results
Morbidity and mortality
Treatment-related mortality (TRM) for VIP-E SDC was 1 of 32 (3%) in LS-NSCLC, and 6 of 75 (8%) in ES NSCLC (overall TRM 7 of 107, i.e., 6.5%). TRM for VIC-E HDC was 1 of 25 (4%).
Treatment results
Thirty-five of 102 evaluable patients responded to VIP-E SDC (2 CR/33 PR), 33 patients showed no change (NC); the remaining 33% had progressive disease (PD). The objective response rate was 68% in LS-NSCLC, and 23% in ES-NSCLC. The mean duration of response was 12 months in LS-NSCLC, and two months in ES-NSCLC. The mean duration of survival was 20 months in LS-NSCLC, and seven months in ES-NSCLC. Five-year survival was 12% in LS and 0% in ES-NSCLC. After HDC, 23 of 24 evaluable patients improved or maintained prior responses, one patient showed NC. The mean duration of response was 17 months in LS-NSCLC, and six months in ES-NSCLC. The mean survival was 24 months in LS-NSCLC, and 12 months in ES-NSCLC. The five-year survival was 18% in LS, and 0% in ES-NSCLC.
Survival
Of 82 patients receiving SDC only, 79 have died, while three remain alive. All 62 ES-patients have died. Of 20 LS-patients, 17 have died, one is alive in relapse, and two in CR. The mean duration of survival was 19.9 months in LS-NSCLC, and 7.2 months in ES-NSCLC. Five-year relapse-free survival (RFS) by Kaplan-Meier was 12% in LS-NSCLC (95% CI 4%-20%) and 0% in ES-NSCLC (Figure 1) .
Twenty-five of 107 (23%) patients proceeded to HDC. Of 12 patients with LS-NSCLC who underwent HDC 10 have died, and two are alive in first CR at 44+ or second CR at 76+ months. The latter patient developed a solitary cerebral metastasis 12 months after HDC which was surgically resected; remarkably, the patient has since remained in remission for 64+ months. All of the ES-NSCLC patients receiving HDC have died. Their mean survival was 24 for LS-NSCLC, and 12 months for ES-NSCLC. Five-year relapse-free survival (RFS) by Kaplan-Meier was 18% in LS-NSCLC (95% CI: 7%-28%), and 0% in ES-NSCLC (Figure 1 ).
Discussion
Our trial was designed to assess the feasibility and activity of VIP-E SDC and VIC-E HDC as part of a multi-modality treatment protocol for advanced NSCLC. When compared to the results of other SDC regimens with hematopoietic growth-factor (HGF) support [3] , VIP-E SDC seems equivalent with respect to response rates and survival; the same holds true for VIC-E HDC when compared to the few published trials on HDC followed by PBSCT or bone marrow transplantation (ABMT) in advanced NSCLC [4] [5] [6] [7] [8] [9] .
Neither our study nor any of the published ones [3] [4] [5] [6] [7] [8] [9] have produced results consistently superior to non-HGF requiring standard-dose chemotherapies in combination with surgery and thoracic radiation therapy in NSCLC [10] . Within the context of the traditonal armamentarium of cytotoxic drugs, it therefore remains uncertain whether HGF-supported SDC or HDC followed by PBSCT can improve treatment results in NSCLC.
The recent introduction of new active drugs such as doxetaxel and paclitaxel has led to a reexamination of the role of dose-intensified SDC and HDC in NSCLC [11, 12] . Based on a pilot study with encouraging response rates, the Cancer and Leukemia Group B is conducting a trial consisting of two cycles of paclitaxel (250 mg/m 2 ) and carboplatin (AUC 18) supported by PBSCT in patients with locally advanced NSCLC [12] . As in our study, patients then undergo surgical resection, thoracic radiation, or both, based on their response to induction chemotherapy. The trial will examine clinical and pathologic responses to and toxic effects of this HDC regimen in locally advanced NSCLC. The authors stress, however, that regardless of the outcome of this study, large phase III trials will be needed to further define the role of HDC in NSCLC [12] .
In sum, the literature on dose-intensified chemotherapy in NSCLC does not yet provide evidence of a benefit of HGF-supported or PBSCT-supported forms of standard-and high-dose chemotherapies. Whether the incorporation of new cytotoxic agents into established forms of HGF-and PBSCT-supported SDC and HDC will have an impact on this situation, remains to be seen.
As meaningful responses (CR/PR) are achievable only in a subset of NSCLC patients whose pre-treatment characteristics are poorly defined, and since chemotherapy reponses translate into improved survival only in tumors which become operable or in those rare tumors which are also exceptionally radiosensitive, the decision to institute chemotherapy in NSCLC should always be weighed against the risks of treatment-related morbidity and mortality associated with both standarddose and high-dose chemotherapy regimens.
The use of dose-intensified forms of chemotherapy in NSCLC requiring HGF or PBSCT support should therefore, in our view, be strictly limited to controlled settings in formal clinical trials.
